Bilateral implantation of one multifocal IOL power was non-inferior to contralateral implantation of different multifocal IOL powers in improving distance and intermediate visual acuity, according to a study. However, contralateral implantation yielded superior near vision.“Contralateral implantation might be more beneficial for reading than bilateral implantation. Thus, patients demanding spectacle independence when reading would benefit from contralateral implantation,” corresponding author Soraya M.R. Jonker, MD, and colleagues said in the study, published in the Journal of Cataract and Refractive Surgery.
Vision screening for refractive error, early eye disease may help reduce unnecessary vision loss
By 2050, non-Hispanic white individuals are still expected to represent the largest prevalence of vision impairment cases in the United States. Increasing vision screening and intervention for refractive error and early eye disease may help reduce that…
Spark reports $25.6 million net loss in first quarter
Spark Therapeutics reported a net loss applicable to common stockholders of $25.6 million, or $0.95 per basic and diluted share, in the first quarter compared with a net loss of $10.4 million, or $0.58 per basic and diluted share, in the same quarter o…
Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that clinical data from the company’s Phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article titled “Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression,” which is currently available online
RetroSense Therapeutics Selected as a Red Herring Top 100 North America Winner
ANN ARBOR, Mich.–(BUSINESS WIRE)–Retro-Sense has been selected as a Red Herring Top 100 North America winner, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.
Eye Benefits Last 4 Years Past Tight Glucose Control: ACCORDION
In this ACCORD follow-up in patients with longstanding type 2 diabetes plus cardiovascular disease, intensive glycemic control reduced the risk of retinopathy progression years later, in a “legacy effect.”
Medscape Medical News